When will the patents on SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER expire, and when will generic SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	potassium chloride; sodium chloride	INJECTABLE;INJECTION	018722-004	Nov 9, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 1, 2026

Investment Scenario and Fundamentals Analysis for Sodium Chloride 0.9% and Potassium Chloride 0.3% in Plastic Containers (IV Fluids)

Executive summary: Sodium chloride 0.9% with potassium chloride 0.3% in plastic containers is a mature, commoditized IV electrolyte solution segment where investment outcomes are driven by (1) supply reliability and regulatory compliance, (2) manufacturing scale and container-partner economics, (3) price pressure from generics and private-label products, and (4) working-capital intensity tied to long shelf-life but fast-moving procurement. Patent exclusivity is typically limited to container/formulation-specific improvements rather than broad platform IP, shifting investor focus toward site-level execution and reimbursement dynamics more than patent-led value capture.

What is sodium chloride 0.9% and potassium chloride 0.3% in plastic container used for?

Featured snippet answer: It is an IV electrolyte solution used to provide sodium, chloride, and small-dose potassium in patients requiring fluid and electrolyte replacement, often in inpatient settings where controlled potassium delivery is needed.

Clinical positioning

Used as a controlled electrolyte infusion for patients who need:
- sodium and chloride replacement (normal saline function)
- limited potassium supplementation (potassium chloride contribution)
Typical use contexts:
- perioperative and post-operative fluid management
- inpatient maintenance and replacement regimens
- patients with risk-managed potassium needs where clinicians prefer premixed dosing

Patient safety and labeling constraints that shape demand

Product labeling and stability expectations matter for procurement committees:
- potassium delivery is smaller than full “KCl repletion” products
- compatibility and administration guidance drive nurse and pharmacist adoption
Procurement tends to favor suppliers with:
- consistent container configuration
- predictable lot release and documentation
- stable supply and low backorder risk

What is the Orange Book status of sodium chloride 0.9% and potassium chloride 0.3% in plastic container?

Featured snippet answer: For most simple IV solutions of common electrolytes, the value chain is usually dominated by non-patent exclusivities and market authorization rather than long-term Orange Book patent barriers.

How Orange Book listings typically impact this category

In electrolyte IV solutions, patents (if present) commonly cluster around:
- specific packaging formats or container materials
- stability or manufacturing process improvements
- colorants, surfactants, or trace-impurity control methods (less common for simple salts)
Even when listed, these often expire earlier than competitive life cycles, leading to a generics-dominated market.

Practical consequence for investors

Entry barriers are more operational than legal:
- cGMP execution and validated stability
- container integrity and leachables extractables controls
- regulatory inspections and batch consistency
Portfolio strategy should assume eventual competitive parity unless a company controls a differentiated packaging supply chain or has a defensible quality/manufacturing advantage.

What patents protect sodium chloride 0.9% and potassium chloride 0.3% in plastic containers, and how long do they last?

Featured snippet answer: For this drug class, the active substances (sodium chloride and potassium chloride) are established and IP is usually limited to incremental improvements rather than composition-of-matter dominance.

Likely patent estate architecture (investment-relevant patterns)

Composition-level coverage is unlikely to be broad because:
- both salts are long-established
- premixed electrolyte blends are typically treated as incremental formulation improvements
Real-world protection often comes from:
- container technology and compatibility claims
- manufacturing processes controlling particulate matter, pH, osmolarity range, and impurity thresholds
- specific shelf-life and storage condition claims linked to a process or container system

Timing implications

If a company relies on patent life for valuation, it should model:
- earlier expiration of incremental patents
- quick competitive response once regulatory and manufacturing readiness are achieved
Without a verifiable, current Orange Book patent backbone (composition or method) tied to the exact marketed product, investors should treat patent protection as secondary to supply and execution.

When does sodium chloride 0.9% and potassium chloride 0.3% lose exclusivity for generic competition?

Featured snippet answer: Exclusivity loss typically occurs early in the product lifecycle relative to branded scale because the ingredients are generic and any exclusivity is usually tied to product-specific approvals or packaging/process improvements.

Key drivers of generic entry

Regulatory readiness:
- stability bridging
- container-compatibility evidence
- bio-equivalence is not usually the economic bottleneck for IV solutions; CMC is
Commercial conditions:
- hospital group contracting and rebid cycles
- wholesalers’ assortment strategies
- price erosion once multiple suppliers can meet volume needs

Investment modeling guidance

Build scenarios that assume:
- rapid competitive absorption after any incremental exclusivity ends
- margin compression that tracks bulk procurement trends
Under these assumptions, the “winner” is the lowest total landed cost with reliable delivery and consistently compliant quality documentation.

What generic entry risks exist for sodium chloride 0.9% and potassium chloride 0.3% in plastic containers?

Featured snippet answer: The main risks are not Paragraph IV litigation but supply-based and CMC-based entry, which still compresses pricing.

CMC and quality risks that accelerate or block entry

Accelerators:
- established manufacturing capability for IV electrolytes
- established container partnerships
- proven stability data for the specific container system
Blockers:
- container change requirements and leachables/extractables (extractables) burdens
- impurity control and particulate monitoring performance
- batch release failures or inspection outcomes

Consequence

Price declines can be driven by:
- multiple entrants with validated CMC
- hospital substitution policies
- distributor-driven price competition

How does this IV electrolyte product compare with competing normal saline or KCl premixes?

Featured snippet answer: Compared with plain sodium chloride 0.9%, the added potassium chloride shifts the product into “electrolyte replacement with controlled K+ delivery,” which changes compatibility workflows, pharmacy mixing policies, and contracting preferences.

Competitive set archetypes

Normal saline 0.9% alone (lower complexity)
Premixed sodium chloride plus potassium chloride at different concentrations (dose-specific)
Larger potassium strength KCl premixes (higher repletion intent)
Combination fluids used in maintenance protocols (different osmolarity and electrolyte ratios)

Where procurement differentiates

Dose fit:
- potassium level must match clinical protocol ranges
Administration workflow:
- premix reduces pharmacy compounding workload
Substitution:
- hospitals prefer suppliers that can cover shortages across their formularies

What formulations are protected by patents or trade protections in this segment?

Featured snippet answer: Protection is most likely tied to container and manufacturing process improvements rather than broad formulation IP for common electrolytes.

Container-driven differentiation

Plastic container systems can influence:
- compatibility with electrolytes
- extractables and leachables profile
- administration set compatibility
If a supplier has a long-term container supply contract, it gains resilience during supply disruptions, which can support pricing stability.

Manufacturing-driven differentiation

Stability validation methods
Particle monitoring and controls
pH and osmolarity tight-spec capability
Documentation maturity for rapid regulatory maintenance

What patent litigation affects sodium chloride/potassium chloride IV solutions?

Featured snippet answer: For this category, litigation is not typically the primary event that determines market access. Competitive pressure is more commonly driven by CMC readiness and contracting cycles than patent disputes.

What investors should still watch

Any litigation signals tied to:
- container-specific claims
- process-specific claims
- product listing disputes in FDA systems
Even limited litigation can affect supply timelines, creating temporary pricing opportunities.

How do FDA regulatory milestones and CMC requirements shape market entry?

Featured snippet answer: For IV electrolyte solutions, CMC and container-system validation dominate the pathway to approval and post-approval continuity.

Regulatory and quality workstreams that matter commercially

Container integrity validation:
- seal stability
- compatibility
- extractables/leachables
Shelf-life and stability:
- accelerated and real-time stability
- microbial and chemical stability confirmation
Sterility assurance and particulate control:
- lot release parameters
- visual inspection processes
Inspection readiness:
- batch traceability
- deviations management
- CAPA maturity

Investment consequence

The cost to enter can be high even without major IP barriers.
Investors should value companies with:
- mature sterile manufacturing systems
- consistent inspection outcomes
- scalable bottling/packaging lines matched to hospital demand spikes

Which companies compete in this market, and who wins contracts?

Featured snippet answer: In commoditized IV fluids, contract wins typically correlate with supply reliability, service-level performance, and total cost rather than claims of clinical superiority.

Contracting dynamics

Hospital group purchasing organizations (GPOs) drive bulk awards and rebids.
Wholesaler allocation during supply stress can reshape share quickly.
Substitution policies allow rapid switching among equivalents once availability improves.

Investor implication

Due diligence should prioritize:
- distribution reach and allocation history
- manufacturing capacity and redundancy
- past performance in sterile product outages
- quality agreement track record with major customers

What is the revenue exposure for investors in sodium chloride/potassium chloride IV solutions?

Featured snippet answer: Revenue is exposed to price compression and procurement re-contracting cycles, but can also benefit from supply shortages and contracted base volume.

Key revenue drivers

Contracted volumes:
- multi-quarter agreements reduce volatility
Pricing mechanics:
- benchmark-driven pricing and wholesale margin effects
Mix:
- container size and delivery format can influence customer preference and shipping cost economics

Key downside drivers

Margin compression:
- new entrants increase competitive intensity
Supply interruptions:
- sterile manufacturing disruptions cause volume loss and can trigger penalties in supply agreements
Quality events:
- recall or warning letters can end access to high-volume customers

How strong is the fundamental economics of IV electrolyte solutions?

Featured snippet answer: The segment is typically low-margin and high-volume, with profitability supported by manufacturing scale, yield, low defect rates, and reliable fulfillment rather than IP-led pricing power.

Profitability levers

Capacity utilization in sterile lines
Yield and batch acceptance rates
Lower per-unit packaging and container procurement costs
Logistics efficiency and reduced damage rates
Strong change control and regulatory continuity

Capital allocation considerations

Investors should treat capex as a capacity and compliance tool:
- redundant sterile lines
- validated container packaging systems
- automation for particulate monitoring and inspection
If a company cannot sustain compliance performance through ramp-up, capex becomes a risk amplifier.

What manufacturing and IP barriers prevent low-cost entry?

Featured snippet answer: The barriers are mainly CMC and compliance, not patent exclusivity.

Barrier map

Sterile manufacturing:
- process validation and aseptic controls
Container system validation:
- leachables/extractables and compatibility
Quality systems:
- deviation handling
- batch record integrity
Regulatory maintenance:
- supplements and stability updates

Where moat can exist

Moat is most plausible through:
- long-term container supply agreements
- consistently high batch acceptance and low inspection risk
- customer qualification velocity through proven documentation and service performance

Scenario analysis: How does an investment case perform under baseline, competitive, and shortage conditions?

Featured snippet answer: Best-case outcomes come from supply reliability during constrained periods and stable contracts; worst-case outcomes come from rapid price erosion after new entrants plus any quality disruptions.

Baseline scenario (most likely)

Stable contracted volume with modest price pressure
Margin supported by scale and high batch acceptance
Limited capex additions

Key investment KPI targets

on-time supply rate
batch acceptance rate
gross margin stability after price resets
inspection outcomes

Competitive scenario (bear case)

New entrants or expanded capacity drives price compression
Hospital rebids reduce base volume
Higher marketing and service costs to maintain share

Key risk KPIs

declining net selling price
increased customer churn at contract renewal
rising freight or damage costs

Shortage scenario (bull case)

Supply constraints across sterile manufacturing raise available allocations
Customers lock in volume via emergency buys or shorter rebid cycles at better economics

Key upside KPIs

ability to fulfill through backlog
minimal lot rejection during demand spikes
rapid regulatory and distribution execution

Key Takeaways

This IV electrolyte premix is a mature, heavily procurement-driven market where valuation depends more on manufacturing execution and supply reliability than on long-term patent exclusivity.
Patent protection, if any, is likely incremental and container/process-related, which supports a shallow long-run moat.
Competitive entry is typically enabled by CMC readiness and container system validation rather than Paragraph IV litigation dynamics.
The investment edge comes from operational resilience: sterile capacity redundancy, container supply security, high batch acceptance, and clean regulatory history.
Revenue is exposed to price erosion at contract rebids and protected primarily by contracted base volume and fulfillment performance during shortages.

FAQs

How do container sizes (e.g., bag volumes) affect pricing and contracting for IV electrolyte solutions?
What CMC evidence is most likely to slow entry for sodium chloride/potassium chloride premixes?
Do hospital formularies treat potassium-containing saline premixes as interchangeable with pharmacy-compounded mixtures?
What operational metrics predict future recall risk for sterile IV solutions?
How should investors value supplier capacity in sterile manufacturing for commoditized IV products?

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA’s Orange Book database).
U.S. Food and Drug Administration. Drug Approval Reports and approval histories. (Accessed via FDA databases).
U.S. Food and Drug Administration. Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. (Published guidance).

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER